JPS60148561A - Blood circuit chamber - Google Patents
Blood circuit chamberInfo
- Publication number
- JPS60148561A JPS60148561A JP59002635A JP263584A JPS60148561A JP S60148561 A JPS60148561 A JP S60148561A JP 59002635 A JP59002635 A JP 59002635A JP 263584 A JP263584 A JP 263584A JP S60148561 A JPS60148561 A JP S60148561A
- Authority
- JP
- Japan
- Prior art keywords
- chamber
- blood
- mesh
- blood circuit
- circuit chamber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims description 33
- 210000004369 blood Anatomy 0.000 title claims description 33
- 239000012528 membrane Substances 0.000 description 6
- 230000023555 blood coagulation Effects 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 238000003466 welding Methods 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Landscapes
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- External Artificial Organs (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は、血液浄化及びその他の血液体外循環において
、血液を血液処理装置に導き、−処理された血液を再び
体内に戻すための血液回路で使用するチャンバーに関す
るものである。DETAILED DESCRIPTION OF THE INVENTION (Industrial Application Field) The present invention relates to a blood circuit for guiding blood to a blood processing device and returning the treated blood to the body in blood purification and other extracorporeal blood circulation. This relates to the chamber used in
(従来技術と問題点)
血液の体外循環処理においては、エアートラップ及び圧
力緩和のために、血液回路内にチャンバーを設け、さら
に、チャンバー内部には、異物除去のためメツシュを配
置している。(Prior Art and Problems) In extracorporeal circulation treatment of blood, a chamber is provided in the blood circuit for air trapping and pressure relief, and a mesh is placed inside the chamber to remove foreign substances.
従来使用されている血液回路用チャンバーは、普通、第
1図に示すように、直径15〜25IIII11.長さ
40〜l?Ommのほぼ円筒状のもので(直径/長さ≦
0.5が好ましい)、チャン/へ一胴部に内接固定され
たメツシュによって、チャンへ−内は、血液導入側と血
液排出側の一ト下2区画に分割されている。Conventionally used blood circuit chambers usually have a diameter of 15 to 25III11, as shown in FIG. Length 40~l? Omm, almost cylindrical (diameter/length ≦
(preferably 0.5), the inside of the chamber is divided into two sections, a blood introduction side and a blood discharge side, by a mesh internally fixed to the body of the chamber.
第1図の従来型チャン/へ一では、生理食塩水充填の際
、メンシュとチャンバー胴部の界面部(A)には、エア
ーが溜り易く、無抗凝固剤透析や血液凝固系活性の強い
患者では、メンシュ部分に凝塊が発生し、メツシュ膜面
積が十分有効に利用できず圧の一ヒ昇を伴う場合がある
。 また、メツシュをチャンバー胴部に固定した構造か
ら、メツシュの有効膜面積には限界があり、凝塊、圧上
肩等を生起し易い欠点がある。In the conventional chamber/height chamber shown in Figure 1, air tends to accumulate at the interface between the mensch and the chamber body (A) when filling with physiological saline, which causes dialysis without anticoagulants and strong blood coagulation system activity. In patients, coagulation occurs in the mensch area, and the area of the mesh membrane cannot be used effectively enough, resulting in a sudden increase in pressure. Furthermore, due to the structure in which the mesh is fixed to the body of the chamber, there is a limit to the effective membrane area of the mesh, and there is a drawback that coagulum, pressure shoulders, etc. are likely to occur.
rに、従来型チャンバーは、例えば第1図(a)型のも
のでは、胴部(1) 、 、)、端部(2)、下端部(
3)、血液導入管(4)、血液排出管(5)、メツシュ
(6)の各単位部材を、少くとも4工程によって組立て
るもので、本質的に多工程を必要とし、生産性の低下と
コストアップをまぬがれない。For example, the conventional chamber of the type shown in FIG.
3) Each unit member of the blood inlet tube (4), blood outlet tube (5), and mesh (6) is assembled in at least four steps, which essentially requires multiple steps and reduces productivity. We cannot avoid cost increases.
特に、メツシュ(6)を取り付ける工程は、熱溶着、レ
ーザー溶着であり、特殊な技術を必要とする−に、メツ
シュそのものの構造も成型が容易なものではなく、血液
回路全体のコストアップ、低生産性の主要因となってい
る。In particular, the process of attaching the mesh (6) involves heat welding and laser welding, which requires special techniques.The structure of the mesh itself is also not easy to mold, which increases the cost of the entire blood circuit and reduces costs. It is a major factor in productivity.
(発明の目的)
本発明は、上述の如き従来の問題点を改善し、高性能で
しかも生産性の高い改良型チャンバーを提供するもので
ある。(Object of the Invention) The present invention improves the above-mentioned conventional problems and provides an improved chamber with high performance and high productivity.
(発明の構成と作用)
本発明の血液回路用チャンバーは、チャンバー内を血液
導入区画と血液排出区画の2区画に分割するように、メ
・ンシュをチャンバーの上下の両端部で内接固定した点
に特徴を有するものである。(Structure and operation of the invention) The blood circuit chamber of the present invention has a mesh fixed internally at both upper and lower ends of the chamber so as to divide the chamber into two compartments, a blood introduction compartment and a blood discharge compartment. It is characterized by points.
即ち、第2図(d)に示すように、チャンバー中に内蔵
されたメツシュ(6)は、チャンバーの1一端部(2)
と下端部(3)および胴部(1) (1’)に内接固定
されており、血液導入管(4)が開口する区画(7)と
、血液排出管(5)が開口する区画(8)との2区画に
、チャンバー内を左右に分割している。That is, as shown in FIG. 2(d), the mesh (6) built into the chamber is located at one end (2) of the chamber.
and the lower end part (3) and the body part (1) (1') are inscribed and fixed, and there are a compartment (7) where the blood inlet pipe (4) opens, and a compartment (7) where the blood discharge pipe (5) opens. 8) The inside of the chamber is divided into two sections, left and right.
チャンバーの形状としては、特に限定されるものではな
い。 第1図に示すようなウェルター型(b)でも、一
端のみが細くなったもの(a)でも、あるいは、両端が
平担なものでも、円筒状に近いものであれば、どのよう
な形でも良い。The shape of the chamber is not particularly limited. It can be of any shape as long as it is almost cylindrical, whether it is a welter type (b) as shown in Figure 1, a type with only one end tapered (a), or a type with both ends flat. good.
なお、明細書中の「」二端部」、「下端部」、「両端部
」とは、ウェルター型のようにチャンバー内径が次第に
細くなっていく場合には、内径が変化している部分を指
すものとする。In addition, in the specification, "two ends", "lower end", and "both ends" refer to the part where the inner diameter changes when the inner diameter of the chamber gradually becomes thinner, such as in a welter type. shall point.
メツシュは、第2図(a)に示すように、両端部(2)
(3)に対して垂直に固定する必要はなく、自由に傾
斜して取付けることもできる。 第2図(b)の例では
、メツシュ中心線αと血液排出管の中心延長線βは、角
度γの傾きを形成している。The mesh has both ends (2) as shown in Figure 2(a).
There is no need to fix it perpendicularly to (3), and it can be installed at any angle. In the example of FIG. 2(b), the mesh center line α and the central extension line β of the blood discharge tube form an inclination of an angle γ.
好ましいメツシュの傾斜度は、γ≦306である。A preferable mesh slope is γ≦306.
メツシュの接着手段としては、接着剤、超音波、レーザ
ー等の物理的接着、成形時の溶融接着、または封入など
、その手段は特に問うものではない。The means for adhering the mesh may be any adhesive, physical adhesion such as ultrasonic waves, laser, etc., melt adhesion during molding, or encapsulation.
第3図は、本発明チャンバーにおける、メツシュの固定
例を示すものである。 (a)は平板状メツシュを、第
2図(a)のように取付けたもので、(b)は波形メツ
シュを、(c)は円筒状メツシュを増刊けた例を示す。FIG. 3 shows an example of fixing the mesh in the chamber of the present invention. (a) shows a flat mesh attached as shown in FIG. 2(a), (b) shows a corrugated mesh, and (c) shows an example in which a cylindrical mesh is added.
本Julノチャン/へ−では、メツシュの濾過面積を自
由に変えることができ、(b)のように波形メツシュに
すれば、膜面積を特に増大できる。In this case, the filtration area of the mesh can be changed freely, and by using a corrugated mesh as shown in (b), the membrane area can be particularly increased.
このようにメツシュ膜面積を増大すれば、チャンバーの
小型化が可能となる。By increasing the mesh membrane area in this way, it is possible to downsize the chamber.
また、無抗凝固剤透析によりメツシュ部分に凝血が発生
した場合にも、第4図に示すように、凝血部分を順次上
げて行くことにより、内圧の上昇を防ぐことができるの
で、透析時の回路内圧の管理が容易である。Additionally, even if blood clots occur in the mesh area due to anticoagulant-free dialysis, as shown in Figure 4, by raising the blood clotting area one by one, it is possible to prevent the internal pressure from increasing. Control of circuit internal pressure is easy.
更に、本発明のチャンバーは、その製作工程を例えば以
下の(イ)(ロ)の順序にすることによって、従来のキ
ャップ溶着、メンシュ溶着の工程を省くことが可能であ
り、生産性を高めることができる。Furthermore, the chamber of the present invention can omit the conventional cap welding and mensch welding processes by performing the manufacturing process in the following order (a) and (b), thereby increasing productivity. I can do it.
(イ)金型により作製したチャンバー片側胴部(+)の
−1−に、メツシュ(6)をのせる。(a) Place the mesh (6) on the -1- part of the body part (+) on one side of the chamber made using a mold.
(ロ)金型により作製したチャンバー片側胴部(1)を
のせ、貼り合せる。(b) Place the body part (1) on one side of the chamber made using a mold and bond it together.
なお1本発明のチャンバーは、図示していないが、圧力
モニター、レベル調整管等を具備しても良い。Although not shown, the chamber of the present invention may be equipped with a pressure monitor, a level adjustment pipe, etc.
次(と、本発明を実施例によって、更に説明する。Next, the present invention will be further explained with reference to Examples.
(実施例)
直径20fflI11、長さ150mm (7)チャン
バーニおいて、本発明の第2図(a)型、従来の第1図
(a)型(メツシュが門になっている)、第1図(b)
型(メ、シュが凸になっている)の3種のチャンバーに
ついて、下記の条件で試験した。(Example) Diameter 20fflI11, length 150mm (7) In the chamber, the type shown in Fig. 2 (a) of the present invention, the conventional type shown in Fig. 1 (a) (the mesh is a gate), and the type 1 shown in Fig. Figure (b)
Three types of chambers (with convex sides) were tested under the following conditions.
膜面積3cm′″〜50crn’のポリエチレン製70
メツシユのチャンバーメツシュを使用し、開始の際、生
理食塩水1.5文を使用したが、特別なエアー抜きは行
わなかった。Made of polyethylene 70 with a membrane area of 3cm''~50crn'
A mesh chamber mesh was used, and 1.5 g of saline was used at the start, but no special air bleeding was performed.
同一・の試験動物により、血液1100mJl/分、ヘ
パリン量は循環前50単位/kg、循環時500単位/
時の条件で、5時間の体外循環を行った。 この時の血
液処理装置内および血液回路用チャンバー内における凝
血、残血状況を表に示す。In the same test animal, blood was 1100 mJl/min, heparin amount was 50 units/kg before circulation, and 500 units/kg during circulation.
Extracorporeal circulation was performed for 5 hours under the following conditions. The blood clotting and remaining blood conditions in the blood processing device and the blood circuit chamber at this time are shown in the table.
尚、血液処理装置は、内径200川のキュプラアンモニ
ウムレーヨン小空糸を約1万木用いた膜面積1.0m’
のものを使用した。The blood processing device has a membrane area of 1.0 m' using approximately 10,000 small cuproammonium rayon fibers with an inner diameter of 200 mm.
I used the one from
表からも明らかなように、本発明のチャンバーにおいて
は、従来型チャンバーに比較して、エアー抜けの改善等
により、特にチャンバー内での凝血、残血の著しい減少
がみちれた。 従って、本発明のチャンバーは、特に無
抗凝固や血液流量の少ない透析に効果が期待される。As is clear from the table, in the chamber of the present invention, as compared to the conventional chamber, blood coagulation and residual blood in the chamber were significantly reduced due to improved air release, etc. Therefore, the chamber of the present invention is expected to be particularly effective in dialysis without anticoagulation and with low blood flow rate.
第1図は従来型チャンバー、第2乃至第4図は本発明の
改良チャンバーの説明図で、第3図は、種々の改良チャ
ンバーの横断面図、第4図は、血液循環状況を示す図で
ある。
1.1 胴部 5 血液排出管
2 上端部 6 メツシュ
3 下端部 7 血液導入区画
4 血液導入管 8 血液排出区画
代理人 弁理士 佐々木 俊哲
第1図
第2図
(a) (b)
第3図
(a)
″lA4図Fig. 1 is a conventional chamber, Figs. 2 to 4 are explanatory diagrams of the improved chamber of the present invention, Fig. 3 is a cross-sectional view of various improved chambers, and Fig. 4 is a diagram showing the blood circulation situation. It is. 1.1 Torso 5 Blood discharge tube 2 Upper end 6 Mesh 3 Lower end 7 Blood introduction section 4 Blood introduction tube 8 Blood discharge section Agent Patent attorney Toshitetsu Sasaki Figure 1 Figure 2 (a) (b) 3 Figure (a) ″lA4 diagram
Claims (1)
固定されたメツシュによって、チャンノく一内を血液導
入区画と血液排出区画に分割したことを特徴とする、血
液回路チャンバー。A blood circuit chamber, characterized in that the inside of the channel is divided into a blood introduction section and a blood discharge section by meshes inscribed and fixed in the channel at both ends of the chamber.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP59002635A JPS60148561A (en) | 1984-01-12 | 1984-01-12 | Blood circuit chamber |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP59002635A JPS60148561A (en) | 1984-01-12 | 1984-01-12 | Blood circuit chamber |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS60148561A true JPS60148561A (en) | 1985-08-05 |
Family
ID=11534841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP59002635A Pending JPS60148561A (en) | 1984-01-12 | 1984-01-12 | Blood circuit chamber |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS60148561A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003024435A (en) * | 2001-07-19 | 2003-01-28 | Jms Co Ltd | Circuit with sterilization filter for automatic peritoneal dialyzer |
US10967168B2 (en) | 2015-03-04 | 2021-04-06 | B. Braun Melsungen Ag | Medical fluid control device and a particulate filter for same |
-
1984
- 1984-01-12 JP JP59002635A patent/JPS60148561A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003024435A (en) * | 2001-07-19 | 2003-01-28 | Jms Co Ltd | Circuit with sterilization filter for automatic peritoneal dialyzer |
US10967168B2 (en) | 2015-03-04 | 2021-04-06 | B. Braun Melsungen Ag | Medical fluid control device and a particulate filter for same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040034317A1 (en) | Method and apparatus for therapeutic apheresis | |
JP4373684B2 (en) | Filter clogging monitoring device and bedside system | |
Westaby | Complement and the damaging effects of cardiopulmonary bypass | |
EP0838226B1 (en) | Extracorporeal blood circulation system for treating inflammatory diseases | |
JP3899128B2 (en) | Apparatus and method for biospecific removal of heparin | |
Arnestad et al. | Formation of cytokines by retransfusion of shed whole blood | |
JP3083378B2 (en) | Monitoring device for blood flow status at shunt formation site | |
JPS60148561A (en) | Blood circuit chamber | |
JP4195858B2 (en) | Plasma export filter device and apparatus for apheresis therapy | |
EP1658126B1 (en) | Surface treatment of the membrane and associated product | |
JP2002143298A (en) | Blood treatment apparatus | |
WO2000012154A1 (en) | Blood processing device | |
JPS6332461B2 (en) | ||
JP2000126286A (en) | Blood treating device | |
JPH09108338A (en) | Blood port and blood processing device using the same | |
JP3257999B2 (en) | Hollow fiber membrane dialyzer | |
JP2000070680A (en) | Hollow fiber module | |
JP2001204816A (en) | Body fluid treatment device for direct blood perfusion | |
Unger et al. | Enhancing filtration rates by the use of blood flow around the capillaries of plasmafilters: an in vitro study | |
US20050045554A1 (en) | Membrane unit element, semipermeable membrane, filtration device, and processes for manufacturing the same | |
JPH0410345B2 (en) | ||
JPH1147567A (en) | Separation membrane and its preparation | |
JPH0229961Y2 (en) | ||
JP3496382B2 (en) | Separation membrane and method for producing the same | |
JPH069664Y2 (en) | Medical drip chamber |